Viiv

Quote
anonymous said:
Haven’t heard -that nice try gilead troll. Cabenuva doesn’t have 3TC
Click to expand...

But Cabenuva does have resistance! While patients are on the medication nonetheless! Great creation ViiV! Dovato patients must be CAREFULLY selected. You guys have created ONE decent molecule (Tivicay) for HIV in the last 25 years. FYI, combining old sh*t doesn’t make it a new drug.
 






anonymous said:
Haven’t heard -that nice try gilead troll. Cabenuva doesn’t have 3TC
Click to expand...
Thought leaders can’t believe, when used exactly right, and after only 1 year, so many patients had integrase resistance in the studies. These 2DR scare the hell out of them, because patients rarely take products exactly right (look at all the community Dovato resistance).
 






anonymous said:
But Cabenuva does have resistance! While patients are on the medication nonetheless! Great creation ViiV! Dovato patients must be CAREFULLY selected. You guys have created ONE decent molecule (Tivicay) for HIV in the last 25 years. FYI, combining old sh*t doesn’t make it a new drug.
Click to expand...
Follow the science and sit with with an “unbiased” expert so you fully understand what the 2DR HIV potency and efficacy are. If patients needed to be carefully selected and had any more resistance then the 3DR hiv compounds neither of them would have A1 DHHS guidelines or a FDA approval or European recommendations! Don’t spew hate and non truthful scenarios. failing on a drug can happen to any of the current drugs- blowing a class hasn’t happened with Dovato or Cabenuva. Be concerned with the number of people failing on other compounds tooz
 






anonymous said:
Thought leaders can’t believe, when used exactly right, and after only 1 year, so many patients had integrase resistance in the studies. These 2DR scare the hell out of them, because patients rarely take products exactly right (look at all the community Dovato resistance).
Click to expand...
What integrase resistance? Other countries subs-types or people pulled from a study and out back on an integrase- that isnt failing integrase and blowing a class
 






anonymous said:
What integrase resistance? Other countries subs-types or people pulled from a study and out back on an integrase- that isnt failing integrase and blowing a class
Click to expand...
When customers tell us about patients developing resistance on Dovato (I’ve had 2 now), are we supposed to report this as an adverse event?
 






anonymous said:
Follow the science and sit with with an “unbiased” expert so you fully understand what the 2DR HIV potency and efficacy are. If patients needed to be carefully selected and had any more resistance then the 3DR hiv compounds neither of them would have A1 DHHS guidelines or a FDA approval or European recommendations! Don’t spew hate and non truthful scenarios. failing on a drug can happen to any of the current drugs- blowing a class hasn’t happened with Dovato or Cabenuva. Be concerned with the number of people failing on other compounds tooz
Click to expand...

What’s “non-truthful” about Cabenuva resistance being seen in the clinical trials despite patients adhering to the painful monthly ass shots? Are you able to market “no resistance” with Cabenuva?
 






anonymous said:
What’s “non-truthful” about Cabenuva resistance being seen in the clinical trials despite patients adhering to the painful monthly ass shots? Are you able to market “no resistance” with Cabenuva?
Click to expand...
Good thing nobody is using Cab-- there were multiple cases of integrase resistance, when taking exactly as directed, after only 48 weeks - scary. We have never seen anything like that
 






anonymous said:
Good thing nobody is using Cab-- there were multiple cases of integrase resistance, when taking exactly as directed, after only 48 weeks - scary. We have never seen anything like that
Click to expand...
Can CAB beat our Dovato 3.9% total market share, 2 years in? 3 years ago, I would have guessed by now and the way leadership was talking Dovato would be near 20%, and CAB launched in 2019 would be over 10%. Today, I’m guessing neither sniff 10%, ever! It’s crazy
 
























anonymous said:
Thought leaders can’t believe, when used exactly right, and after only 1 year, so many patients had integrase resistance in the studies. These 2DR scare the hell out of them, because patients rarely take products exactly right (look at all the community Dovato resistance).
Click to expand...

All the drugs have resistance in the real world when challenged hard enough. Biktarvy and Genvoya have resistance also. Cab had the same rate of resistance that Genvoya had when it launched. CAB resistance did not blow the class...Try again.
 






Botched launches? What other company has a long history of botched product launches? Guess where almost all of our leadership comes from? GSK has embedded itself here at ViiV. Such a shame!
 






anonymous said:
Please give ONE, just ONE reason why one would consistently Rx Dovato 20% of the time over Triumeq, Tivicay + Descovy or better yet Biktarvy?
Click to expand...
Well, you could put in one hand how many idiots actually are writing Dovato 20% of the time. Honestly, thank goodness. That is why we are only hearing about dozens of devastating resistance cases instead of hundreds. Using CAB exactly as directed for only 1 year showed an incredibly high number of resistance cases, including a frightening number resistant to integrase. Fortunately and remarkably, this drug is having a worse launch than Dovato. I don’t think CAB or Dovato will ruin the integrase class, because combined they will never hit the ViiV pre launch goal of 30-35% (that could have destroyed the class). Most likely as niche products, combined, both never top 10% - this will save integrase
 






anonymous said:
Well, you could put in one hand how many idiots actually are writing Dovato 20% of the time. Honestly, thank goodness. That is why we are only hearing about dozens of devastating resistance cases instead of hundreds. Using CAB exactly as directed for only 1 year showed an incredibly high number of resistance cases, including a frightening number resistant to integrase. Fortunately and remarkably, this drug is having a worse launch than Dovato. I don’t think CAB or Dovato will ruin the integrase class, because combined they will never hit the ViiV pre launch goal of 30-35% (that could have destroyed the class). Most likely as niche products, combined, both never top 10% - this will save integrase
Click to expand...
I had a Provider today say the FDA might pull Dovato because of the real world resistance- is this possible? I know there has been a lot of resistance, but would they really pull it?
 


















anonymous said:
I had a Provider today say the FDA might pull Dovato because of the real world resistance- is this possible? I know there has been a lot of resistance, but would they really pull it?
Click to expand...
And then we leave the world of make believe snd listen to the conferences and real world doctors talking about biktarvy resistance in a 3DR world - whaaaaaatttt? Let the data and real world speak to itself for dovato- FDA approved and studies continue to repeat performance and so do real patients. Nice try gilead troll
 






anonymous said:
And then we leave the world of make believe snd listen to the conferences and real world doctors talking about biktarvy resistance in a 3DR world - whaaaaaatttt? Let the data and real world speak to itself for dovato- FDA approved and studies continue to repeat performance and so do real patients. Nice try gilead troll
Click to expand...
You need real world patients to talk about real world experience - Almost 3 years after Dovato launch, still scraping the bottom of the barrel with one of the least used products out there doesn’t count.
 












Top Bottom
Back
Quote